BioVersys AG is a Swiss clinical-stage biopharmaceutical company focused on antibacterial products for severe infections caused by multidrug-resistant bacteria. It is headquartered in Basel and listed on SIX under BIOV.
BioVersys AG received FDA approval to enroll U.S. patients in a global Phase 3 trial evaluating BV100 for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, with trial completion expected by end of 2027.
BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07326540 |
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex |
RECRUITING | PHASE3 |
